董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lewis H. Titterton | 男 | Lead Independent Director | 78 | 26.76万美元 | 120.35 | 2023-01-27 |
| Arnold Baskies | 男 | Director | 73 | 26.76万美元 | 5.44 | 2023-01-27 |
| Emily Gottschalk | 女 | Director | 62 | 26.76万美元 | 未持股 | 2023-01-27 |
| Amit Kumar | 男 | Chairman of the Board and Chief Executive Officer | 58 | 215.90万美元 | 319.87 | 2023-01-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael J. Catelani | 男 | President, Chief Operating Officer and Chief Financial Officer | 56 | 184.86万美元 | 25.36 | 2023-01-27 |
| Amit Kumar | 男 | Chairman of the Board and Chief Executive Officer | 58 | 215.90万美元 | 319.87 | 2023-01-27 |
董事简历
中英对照 | 中文 | 英文- Lewis H. Titterton
-
Lewis H. Titterton自2017年7月起担任董事，自2018年7月起担任首席独立董事。他曾于2010年8月至2016年8月担任公司董事，2012年7月至2016年8月担任董事会主席，2012年8月至2012年9月担任临时首席执行官。2018年9月至2019年4月，他担任上市无线技术公司ParkerVision，Inc.的董事会成员。他的背景是高科技，重点是医疗保健，从1989年到2018年10月，他担任多元化医疗服务公司NYMED，Inc.的董事会主席。Titterton先生于1986年创立了MedE美国公司，并于1978年至1986年担任管理和规划服务公司的首席执行官。Titterton先生还于1999年7月至2003年1月担任Anixa Biosciences, Inc.的董事之一。他拥有Albany纽约州立大学的MBA学位和康奈尔大学的学士学位。
Lewis H. Titterton has served as a director since July 2017 and as Lead Independent Director since July 2018. He previously served as a director of the Company from August 2010 through August 2016 as the Chairman of the Board from July 2012 through August 2016 and interim Chief Executive Officer from August 2012 until September 2012. He served on the board of directors of ParkerVision, Inc., a publicly traded wireless technology company, from September 2018 to April 2019. His background is in high technology with an emphasis on health care and he was the Chairman of the Board of Directors of NYMED, Inc., a diversified health services company, from 1989 until October 2018. Mr. Titterton founded MedE America, Inc. in 1986 and was Chief Executive Officer of Management and Planning Services, Inc. from 1978 to 1986. Mr. Titterton also served as one of Anixa Biosciences, Inc.'s Directors from July 1999 to January 2003. He holds an MBA from the State University of New York at Albany, and a B.A. degree from Cornell University. - Lewis H. Titterton自2017年7月起担任董事，自2018年7月起担任首席独立董事。他曾于2010年8月至2016年8月担任公司董事，2012年7月至2016年8月担任董事会主席，2012年8月至2012年9月担任临时首席执行官。2018年9月至2019年4月，他担任上市无线技术公司ParkerVision，Inc.的董事会成员。他的背景是高科技，重点是医疗保健，从1989年到2018年10月，他担任多元化医疗服务公司NYMED，Inc.的董事会主席。Titterton先生于1986年创立了MedE美国公司，并于1978年至1986年担任管理和规划服务公司的首席执行官。Titterton先生还于1999年7月至2003年1月担任Anixa Biosciences, Inc.的董事之一。他拥有Albany纽约州立大学的MBA学位和康奈尔大学的学士学位。
- Lewis H. Titterton has served as a director since July 2017 and as Lead Independent Director since July 2018. He previously served as a director of the Company from August 2010 through August 2016 as the Chairman of the Board from July 2012 through August 2016 and interim Chief Executive Officer from August 2012 until September 2012. He served on the board of directors of ParkerVision, Inc., a publicly traded wireless technology company, from September 2018 to April 2019. His background is in high technology with an emphasis on health care and he was the Chairman of the Board of Directors of NYMED, Inc., a diversified health services company, from 1989 until October 2018. Mr. Titterton founded MedE America, Inc. in 1986 and was Chief Executive Officer of Management and Planning Services, Inc. from 1978 to 1986. Mr. Titterton also served as one of Anixa Biosciences, Inc.'s Directors from July 1999 to January 2003. He holds an MBA from the State University of New York at Albany, and a B.A. degree from Cornell University.
- Arnold Baskies
-
Arnold Baskies，是董事会认证的一般训练的外科医生和外科肿瘤学家，专注于乳腺癌、甲状腺癌、黑色素瘤。他一直担任Virtua Surgical Specialists（多专业实践）的成员（2011年以来）。他曾带领促进最新的手术和非手术技术，其中包括用于治疗乳腺疾病、甲状腺、甲状旁腺的微创手术和高级无线电制导技术。30年的职业生涯中，他一直照顾成千上万的外科手术病人。他以优异成绩获得学士学位。他也曾担任Boston University的美国大学优等生荣誉学会的成员。他毕业于the Boston University School of Medicine，并完成了Boston Medical Center的外科住院实习。他也获得了the National Cancer Institute的肿瘤外科专科训练。
Arnold Baskies,has served as director since August 2020. From 2007 to 2010, Dr. Baskies served as the Chief Medical Officer for the American Cancer Society of New York and New Jersey and was elected as President of the American Cancer Society for New York and New Jersey in September 2010. In 2016, he served as Science Officer to the ACS National Board, and in 2017, he served as Chairman of the National Board of Directors of ACS. He currently serves on the Executive Committee of the Commission on Cancer and the Global Breast Cancer Initiative of the World Health Organization (WHO). Dr. Baskies is the recipient of major awards in cancer research from the Society of Surgical Oncology, the American Radium Society, the Society of Head and Neck Surgeons and the American Cancer Society. In addition, he is a recipient of the St. George Medal from ACS, the recipient of the EPIC Award from the NJ Institute of Nursing and awarded the Silver Chalice Award from the American Cancer Society, for his role in providing leadership in cancer prevention and treatment for the citizens of New Jersey. Dr. Baskies has maintained a medical practice in southern New Jersey for 44 years and is a Clinical Professor of Surgery at Rowan School of Medicine and Jefferson School of Nursing. He holds major state and national leadership roles in cancer prevention and treatment. He has personally treated over 5,000 patients with various types of cancer and performed over 10,000 surgical procedures. Dr. Baskies received his Bachelor of Arts degree summa cum laude, Phi Beta Kappa, at Boston University. He graduated from the Boston University School of Medicine and completed his surgical residency at Boston Medical Center and his fellowship in surgical oncology at the National Cancer Institute. - Arnold Baskies，是董事会认证的一般训练的外科医生和外科肿瘤学家，专注于乳腺癌、甲状腺癌、黑色素瘤。他一直担任Virtua Surgical Specialists（多专业实践）的成员（2011年以来）。他曾带领促进最新的手术和非手术技术，其中包括用于治疗乳腺疾病、甲状腺、甲状旁腺的微创手术和高级无线电制导技术。30年的职业生涯中，他一直照顾成千上万的外科手术病人。他以优异成绩获得学士学位。他也曾担任Boston University的美国大学优等生荣誉学会的成员。他毕业于the Boston University School of Medicine，并完成了Boston Medical Center的外科住院实习。他也获得了the National Cancer Institute的肿瘤外科专科训练。
- Arnold Baskies,has served as director since August 2020. From 2007 to 2010, Dr. Baskies served as the Chief Medical Officer for the American Cancer Society of New York and New Jersey and was elected as President of the American Cancer Society for New York and New Jersey in September 2010. In 2016, he served as Science Officer to the ACS National Board, and in 2017, he served as Chairman of the National Board of Directors of ACS. He currently serves on the Executive Committee of the Commission on Cancer and the Global Breast Cancer Initiative of the World Health Organization (WHO). Dr. Baskies is the recipient of major awards in cancer research from the Society of Surgical Oncology, the American Radium Society, the Society of Head and Neck Surgeons and the American Cancer Society. In addition, he is a recipient of the St. George Medal from ACS, the recipient of the EPIC Award from the NJ Institute of Nursing and awarded the Silver Chalice Award from the American Cancer Society, for his role in providing leadership in cancer prevention and treatment for the citizens of New Jersey. Dr. Baskies has maintained a medical practice in southern New Jersey for 44 years and is a Clinical Professor of Surgery at Rowan School of Medicine and Jefferson School of Nursing. He holds major state and national leadership roles in cancer prevention and treatment. He has personally treated over 5,000 patients with various types of cancer and performed over 10,000 surgical procedures. Dr. Baskies received his Bachelor of Arts degree summa cum laude, Phi Beta Kappa, at Boston University. He graduated from the Boston University School of Medicine and completed his surgical residency at Boston Medical Center and his fellowship in surgical oncology at the National Cancer Institute.
- Emily Gottschalk
-
Emily Gottschalk自2019年10月起担任董事会成员。她是一位经验丰富的营销人员，拥有超过30年的为消费者市场开发产品的经验。她自1997年以来一直担任The Garr Group，Inc.的首席执行官，该公司是一家多元化的娱乐和新的产品开发公司，由她创立，向大众、专业和在线市场销售娱乐和一般商品。Gottschalk女士于2017年共同创立了IdeationUSA，LLC，这是一家专注于将创新电子产品引入消费市场的产品开发公司。IdeationUSA确定了市场中的机会，并定义和开发了独特地触碰消费者生活的产品。Ideation同样专注于实体和砂浆，在线和新兴的分销渠道。此前，她曾担任Zany Brainy公司（她推出的儿童教育玩具商店）的营销总监。自1997年以来，Gottschalk&8217；s公司已为美国零售市场生产了超过1.5亿张CD/DVD&8217；s，与英特尔（Intel）合作开发了一款名为RealPad的专有Android平板电脑，并在整个家用和手工艺市场创建了自有品牌。她毕业于康奈尔大学（Cornell University）酒店管理学院，并任职于多个慈善组织的董事会。
Emily Gottschalk has served on Anixa Biosciences, Inc. Board since October 2019. She has been the Chief Executive Officer of The Garr Group, Inc. since 1997 a diverse entertainment and new product development company that she founded that sells entertainment and general merchandise to the mass, specialty and on-line market. The Garr Group identifies "white space" opportunities in the marketplace and defines and develops products that uniquely touch consumers' lives. The Garr Group is equally focused on brick and mortar, on-line and emerging distribution channels. Previously, she was Marketing Director of Zany Brainy, a children's educational toy store that she helped launch. Since 1997 Ms. Gottschalk's companies have produced over 150 million CD's/DVD's to the US retail market, developed a proprietary Android tablet called "RealPad, by AARP" with Intel and has created private label brands across the home, sporting goods and electronics market. She is a graduate of Cornell University's School of Hotel Administration and serves on the board of several philanthropic organizations. - Emily Gottschalk自2019年10月起担任董事会成员。她是一位经验丰富的营销人员，拥有超过30年的为消费者市场开发产品的经验。她自1997年以来一直担任The Garr Group，Inc.的首席执行官，该公司是一家多元化的娱乐和新的产品开发公司，由她创立，向大众、专业和在线市场销售娱乐和一般商品。Gottschalk女士于2017年共同创立了IdeationUSA，LLC，这是一家专注于将创新电子产品引入消费市场的产品开发公司。IdeationUSA确定了市场中的机会，并定义和开发了独特地触碰消费者生活的产品。Ideation同样专注于实体和砂浆，在线和新兴的分销渠道。此前，她曾担任Zany Brainy公司（她推出的儿童教育玩具商店）的营销总监。自1997年以来，Gottschalk&8217；s公司已为美国零售市场生产了超过1.5亿张CD/DVD&8217；s，与英特尔（Intel）合作开发了一款名为RealPad的专有Android平板电脑，并在整个家用和手工艺市场创建了自有品牌。她毕业于康奈尔大学（Cornell University）酒店管理学院，并任职于多个慈善组织的董事会。
- Emily Gottschalk has served on Anixa Biosciences, Inc. Board since October 2019. She has been the Chief Executive Officer of The Garr Group, Inc. since 1997 a diverse entertainment and new product development company that she founded that sells entertainment and general merchandise to the mass, specialty and on-line market. The Garr Group identifies "white space" opportunities in the marketplace and defines and develops products that uniquely touch consumers' lives. The Garr Group is equally focused on brick and mortar, on-line and emerging distribution channels. Previously, she was Marketing Director of Zany Brainy, a children's educational toy store that she helped launch. Since 1997 Ms. Gottschalk's companies have produced over 150 million CD's/DVD's to the US retail market, developed a proprietary Android tablet called "RealPad, by AARP" with Intel and has created private label brands across the home, sporting goods and electronics market. She is a graduate of Cornell University's School of Hotel Administration and serves on the board of several philanthropic organizations.
- Amit Kumar
-
Amit Kumar于2017年7月起担任Anixa Biosciences, Inc.总裁兼首席执行官，2012年11月起担任公司董事，2016年8月起担任董事会主席。2015年6月至2016年8月，他担任公司Vice Chairman of the Board。Kumar博士从2012年9月至2017年7月担任战略顾问。他自2015年6月起担任公司全资子公司Anixa Diagnostics Corporation董事会执行主席。Kumar博士被任命为执行主席后，辞去了自2010年12月以来一直担任的能源公司Geo Fossil Fuels LLC首席执行官的职务。2001年9月至2010年6月，他担任纳斯达克上市生物技术公司CombiMatrix公司的总裁兼首席执行官，并于2000年9月至2012年6月担任董事。他于2000年7月至2007年8月担任上市投资公司Acacia Research Corporation的生命科学副总裁，并于2003年1月至2007年8月担任董事。Kumar博士自2007年6月起担任Ascent Solar Technologies, Inc.的董事会主席，Ascent Solar Technologies, Inc.是一家上市太阳能公司。2004年6月至2018年6月，他担任上市生物技术公司Aeolus Pharmaceuticals，Inc.的董事。Kumar博士是私人生物技术公司Actym Therapeutics的董事长。Kumar博士自2016年起担任美国癌症协会的董事会成员。Kumar博士拥有西方学院的化学学士学位。在斯坦福大学和加州理工学院完成研究生学习后，他在加州理工学院获得博士学位，并在哈佛大学完成博士后培训。并且，如上所述，曾担任多家上市公司的董事和/或高级管理人员。
Amit Kumar has served as Anixa Biosciences, Inc. President and Chief Executive Officer since July 2017 as a director of the Company since November 2012 and as Chairman of the Board since August 2016. From June 2015 until August 2016 he served as Vice Chairman of the Board. Dr. Kumar served as a strategic advisor to the Company from September 2012 until July 2017. He has been Executive Chairman of the board of directors of Anixa Diagnostics Corporation, a wholly-owned subsidiary of the Company since June 2015. Upon his appointment as Executive Chairman, Dr. Kumar resigned from his position as the Chief Executive Officer of Geo Fossil Fuels LLC, an energy company, which he had held since December 2010. From September 2001 to June 2010 he was President and Chief Executive Officer of CombiMatrix Corporation, a NASDAQ listed biotechnology company, and also served as director from September 2000 to June 2012. He was Vice President of Life Sciences of Acacia Research Corporation, a publicly traded investment company, from July 2000 to August 2007 and also served as a director from January 2003 to August 2007. Dr. Kumar has served as Chairman of the board of directors of Ascent Solar Technologies, Inc., a publicly-held solar energy company, since June 2007. He served as a director of Aeolus Pharmaceuticals, Inc., a publicly traded biotechnology company, from June 2004 to June 2018. Dr. Kumar is Chairman of Actym Therapeutics, a private biotechnology company. Dr. Kumar has served on the board of the American Cancer Society since 2016. Dr. Kumar holds an A.B. in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and completed his post-doctoral training at Harvard University. And, as described above, has served as a director and/or officer of various publicly traded companies. - Amit Kumar于2017年7月起担任Anixa Biosciences, Inc.总裁兼首席执行官，2012年11月起担任公司董事，2016年8月起担任董事会主席。2015年6月至2016年8月，他担任公司Vice Chairman of the Board。Kumar博士从2012年9月至2017年7月担任战略顾问。他自2015年6月起担任公司全资子公司Anixa Diagnostics Corporation董事会执行主席。Kumar博士被任命为执行主席后，辞去了自2010年12月以来一直担任的能源公司Geo Fossil Fuels LLC首席执行官的职务。2001年9月至2010年6月，他担任纳斯达克上市生物技术公司CombiMatrix公司的总裁兼首席执行官，并于2000年9月至2012年6月担任董事。他于2000年7月至2007年8月担任上市投资公司Acacia Research Corporation的生命科学副总裁，并于2003年1月至2007年8月担任董事。Kumar博士自2007年6月起担任Ascent Solar Technologies, Inc.的董事会主席，Ascent Solar Technologies, Inc.是一家上市太阳能公司。2004年6月至2018年6月，他担任上市生物技术公司Aeolus Pharmaceuticals，Inc.的董事。Kumar博士是私人生物技术公司Actym Therapeutics的董事长。Kumar博士自2016年起担任美国癌症协会的董事会成员。Kumar博士拥有西方学院的化学学士学位。在斯坦福大学和加州理工学院完成研究生学习后，他在加州理工学院获得博士学位，并在哈佛大学完成博士后培训。并且，如上所述，曾担任多家上市公司的董事和/或高级管理人员。
- Amit Kumar has served as Anixa Biosciences, Inc. President and Chief Executive Officer since July 2017 as a director of the Company since November 2012 and as Chairman of the Board since August 2016. From June 2015 until August 2016 he served as Vice Chairman of the Board. Dr. Kumar served as a strategic advisor to the Company from September 2012 until July 2017. He has been Executive Chairman of the board of directors of Anixa Diagnostics Corporation, a wholly-owned subsidiary of the Company since June 2015. Upon his appointment as Executive Chairman, Dr. Kumar resigned from his position as the Chief Executive Officer of Geo Fossil Fuels LLC, an energy company, which he had held since December 2010. From September 2001 to June 2010 he was President and Chief Executive Officer of CombiMatrix Corporation, a NASDAQ listed biotechnology company, and also served as director from September 2000 to June 2012. He was Vice President of Life Sciences of Acacia Research Corporation, a publicly traded investment company, from July 2000 to August 2007 and also served as a director from January 2003 to August 2007. Dr. Kumar has served as Chairman of the board of directors of Ascent Solar Technologies, Inc., a publicly-held solar energy company, since June 2007. He served as a director of Aeolus Pharmaceuticals, Inc., a publicly traded biotechnology company, from June 2004 to June 2018. Dr. Kumar is Chairman of Actym Therapeutics, a private biotechnology company. Dr. Kumar has served on the board of the American Cancer Society since 2016. Dr. Kumar holds an A.B. in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and completed his post-doctoral training at Harvard University. And, as described above, has served as a director and/or officer of various publicly traded companies.
高管简历
中英对照 | 中文 | 英文- Michael J. Catelani
Michael J. Catelani自2022年4月起担任Anixa Biosciences, Inc.总裁、2017年7月起担任Anixa Biosciences, Inc.首席运营官、2016年11月起担任Anixa Biosciences, Inc.首席财务官。Catelani先生是一位经验丰富的高管，在财务和运营方面拥有30多年的经验。2012年10月至2017年7月，他在生物技术领域的多家老牌私营企业担任合同制首席财务官。他于2015年1月至2017年7月在私营临床研究机构PRC临床研究所的董事会任职。2006年7月，他与人共同创立了一家私人控股的生物技术公司Tacere Therapeutics，Inc，并担任Tacere Therapeutics，Inc的董事长、总裁兼首席财务官，直到2012年10月Tacere Therapeutics，Inc被出售。在Tacere任职期间，Catelani先生在与辉瑞公司建立和管理价值1.5亿美元的药物开发合作关系方面发挥了重要作用，在加入Tacere之前，他曾在Benitec Biopharma Limited董事会任职并担任首席财务官，Benitec Biopharma Limited当时在澳大利亚证券交易所上市的生物技术公司任职。在加入Benitec公司之前，Catelani先生曾在Axon Instruments公司担任副总裁兼首席财务官。Axon Instruments公司是一家在澳大利亚证券交易所上市的美国公司，是生物技术和诊断研究用仪器和软件系统的领先设计商和制造商。在加入Axon之前，他曾在纽约证券交易所上市的品牌消费品公司Media Arts Group，Inc.担任财务副总裁。Catelani先生还与多个行业的几家早期创业公司合作，包括生物技术、清洁技术和零售，担任顾问和管理职务。Catelani先生的职业生涯始于安永会计师事务所，是一名注册会计师（非在职）。他拥有加州州立大学萨克拉门托分校的会计学学士学位和加州大学戴维斯分校的工商管理硕士学位。
Michael J. Catelani,has served as Anixa Biosciences, Inc. President since April 2022, as Anixa Biosciences, Inc. Chief Operating Officer since July 2017 and as Anixa Biosciences, Inc. Chief Financial Officer since November 2016. Mr. Catelani is a seasoned executive with over 30 years of experience in finance and operations. From October 2012 to July 2017, he served as a contract Chief Financial Officer to a number of established privately held businesses in the biotechnology field. He served on the board of directors of PRC Clinical, a privately held clinical research organization, from January 2015 to July 2017. In July 2006, he co-founded Tacere Therapeutics, Inc., a privately held biotechnology company, and served as its Chairman, President and Chief Financial Officer until its sale in October 2012. While at Tacere, Mr. Catelani was instrumental in establishing and managing a $150 million drug development collaboration with Pfizer, Inc. Prior to Tacere, he served on the Board of Directors and was the Chief Financial Officer of Benitec Biopharma Limited, at the time an Australian Securities Exchange-listed biotechnology company. Prior to Benitec, Mr. Catelani served as Vice President and Chief Financial Officer at Axon Instruments, Inc., a U.S. corporation publicly traded on the Australian Securities Exchange that was a leading designer and manufacturer of instrumentation and software systems for biotechnology and diagnostics research. Prior to Axon, he served as the Vice President of Finance for Media Arts Group, Inc., an NYSE-listed branded consumer products company. Mr. Catelani has also worked with several early-stage start-up companies in multiple industries, including biotechnology, cleantech and retail, in advisory and management roles. Mr. Catelani began his professional career at Ernst & Young and is a CPA (Inactive). He holds a B.S. degree in Accounting from California State University, Sacramento and an MBA from the University of California, Davis.- Michael J. Catelani自2022年4月起担任Anixa Biosciences, Inc.总裁、2017年7月起担任Anixa Biosciences, Inc.首席运营官、2016年11月起担任Anixa Biosciences, Inc.首席财务官。Catelani先生是一位经验丰富的高管，在财务和运营方面拥有30多年的经验。2012年10月至2017年7月，他在生物技术领域的多家老牌私营企业担任合同制首席财务官。他于2015年1月至2017年7月在私营临床研究机构PRC临床研究所的董事会任职。2006年7月，他与人共同创立了一家私人控股的生物技术公司Tacere Therapeutics，Inc，并担任Tacere Therapeutics，Inc的董事长、总裁兼首席财务官，直到2012年10月Tacere Therapeutics，Inc被出售。在Tacere任职期间，Catelani先生在与辉瑞公司建立和管理价值1.5亿美元的药物开发合作关系方面发挥了重要作用，在加入Tacere之前，他曾在Benitec Biopharma Limited董事会任职并担任首席财务官，Benitec Biopharma Limited当时在澳大利亚证券交易所上市的生物技术公司任职。在加入Benitec公司之前，Catelani先生曾在Axon Instruments公司担任副总裁兼首席财务官。Axon Instruments公司是一家在澳大利亚证券交易所上市的美国公司，是生物技术和诊断研究用仪器和软件系统的领先设计商和制造商。在加入Axon之前，他曾在纽约证券交易所上市的品牌消费品公司Media Arts Group，Inc.担任财务副总裁。Catelani先生还与多个行业的几家早期创业公司合作，包括生物技术、清洁技术和零售，担任顾问和管理职务。Catelani先生的职业生涯始于安永会计师事务所，是一名注册会计师（非在职）。他拥有加州州立大学萨克拉门托分校的会计学学士学位和加州大学戴维斯分校的工商管理硕士学位。
- Michael J. Catelani,has served as Anixa Biosciences, Inc. President since April 2022, as Anixa Biosciences, Inc. Chief Operating Officer since July 2017 and as Anixa Biosciences, Inc. Chief Financial Officer since November 2016. Mr. Catelani is a seasoned executive with over 30 years of experience in finance and operations. From October 2012 to July 2017, he served as a contract Chief Financial Officer to a number of established privately held businesses in the biotechnology field. He served on the board of directors of PRC Clinical, a privately held clinical research organization, from January 2015 to July 2017. In July 2006, he co-founded Tacere Therapeutics, Inc., a privately held biotechnology company, and served as its Chairman, President and Chief Financial Officer until its sale in October 2012. While at Tacere, Mr. Catelani was instrumental in establishing and managing a $150 million drug development collaboration with Pfizer, Inc. Prior to Tacere, he served on the Board of Directors and was the Chief Financial Officer of Benitec Biopharma Limited, at the time an Australian Securities Exchange-listed biotechnology company. Prior to Benitec, Mr. Catelani served as Vice President and Chief Financial Officer at Axon Instruments, Inc., a U.S. corporation publicly traded on the Australian Securities Exchange that was a leading designer and manufacturer of instrumentation and software systems for biotechnology and diagnostics research. Prior to Axon, he served as the Vice President of Finance for Media Arts Group, Inc., an NYSE-listed branded consumer products company. Mr. Catelani has also worked with several early-stage start-up companies in multiple industries, including biotechnology, cleantech and retail, in advisory and management roles. Mr. Catelani began his professional career at Ernst & Young and is a CPA (Inactive). He holds a B.S. degree in Accounting from California State University, Sacramento and an MBA from the University of California, Davis.
- Amit Kumar
Amit Kumar于2017年7月起担任Anixa Biosciences, Inc.总裁兼首席执行官，2012年11月起担任公司董事，2016年8月起担任董事会主席。2015年6月至2016年8月，他担任公司Vice Chairman of the Board。Kumar博士从2012年9月至2017年7月担任战略顾问。他自2015年6月起担任公司全资子公司Anixa Diagnostics Corporation董事会执行主席。Kumar博士被任命为执行主席后，辞去了自2010年12月以来一直担任的能源公司Geo Fossil Fuels LLC首席执行官的职务。2001年9月至2010年6月，他担任纳斯达克上市生物技术公司CombiMatrix公司的总裁兼首席执行官，并于2000年9月至2012年6月担任董事。他于2000年7月至2007年8月担任上市投资公司Acacia Research Corporation的生命科学副总裁，并于2003年1月至2007年8月担任董事。Kumar博士自2007年6月起担任Ascent Solar Technologies, Inc.的董事会主席，Ascent Solar Technologies, Inc.是一家上市太阳能公司。2004年6月至2018年6月，他担任上市生物技术公司Aeolus Pharmaceuticals，Inc.的董事。Kumar博士是私人生物技术公司Actym Therapeutics的董事长。Kumar博士自2016年起担任美国癌症协会的董事会成员。Kumar博士拥有西方学院的化学学士学位。在斯坦福大学和加州理工学院完成研究生学习后，他在加州理工学院获得博士学位，并在哈佛大学完成博士后培训。并且，如上所述，曾担任多家上市公司的董事和/或高级管理人员。
Amit Kumar has served as Anixa Biosciences, Inc. President and Chief Executive Officer since July 2017 as a director of the Company since November 2012 and as Chairman of the Board since August 2016. From June 2015 until August 2016 he served as Vice Chairman of the Board. Dr. Kumar served as a strategic advisor to the Company from September 2012 until July 2017. He has been Executive Chairman of the board of directors of Anixa Diagnostics Corporation, a wholly-owned subsidiary of the Company since June 2015. Upon his appointment as Executive Chairman, Dr. Kumar resigned from his position as the Chief Executive Officer of Geo Fossil Fuels LLC, an energy company, which he had held since December 2010. From September 2001 to June 2010 he was President and Chief Executive Officer of CombiMatrix Corporation, a NASDAQ listed biotechnology company, and also served as director from September 2000 to June 2012. He was Vice President of Life Sciences of Acacia Research Corporation, a publicly traded investment company, from July 2000 to August 2007 and also served as a director from January 2003 to August 2007. Dr. Kumar has served as Chairman of the board of directors of Ascent Solar Technologies, Inc., a publicly-held solar energy company, since June 2007. He served as a director of Aeolus Pharmaceuticals, Inc., a publicly traded biotechnology company, from June 2004 to June 2018. Dr. Kumar is Chairman of Actym Therapeutics, a private biotechnology company. Dr. Kumar has served on the board of the American Cancer Society since 2016. Dr. Kumar holds an A.B. in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and completed his post-doctoral training at Harvard University. And, as described above, has served as a director and/or officer of various publicly traded companies.- Amit Kumar于2017年7月起担任Anixa Biosciences, Inc.总裁兼首席执行官，2012年11月起担任公司董事，2016年8月起担任董事会主席。2015年6月至2016年8月，他担任公司Vice Chairman of the Board。Kumar博士从2012年9月至2017年7月担任战略顾问。他自2015年6月起担任公司全资子公司Anixa Diagnostics Corporation董事会执行主席。Kumar博士被任命为执行主席后，辞去了自2010年12月以来一直担任的能源公司Geo Fossil Fuels LLC首席执行官的职务。2001年9月至2010年6月，他担任纳斯达克上市生物技术公司CombiMatrix公司的总裁兼首席执行官，并于2000年9月至2012年6月担任董事。他于2000年7月至2007年8月担任上市投资公司Acacia Research Corporation的生命科学副总裁，并于2003年1月至2007年8月担任董事。Kumar博士自2007年6月起担任Ascent Solar Technologies, Inc.的董事会主席，Ascent Solar Technologies, Inc.是一家上市太阳能公司。2004年6月至2018年6月，他担任上市生物技术公司Aeolus Pharmaceuticals，Inc.的董事。Kumar博士是私人生物技术公司Actym Therapeutics的董事长。Kumar博士自2016年起担任美国癌症协会的董事会成员。Kumar博士拥有西方学院的化学学士学位。在斯坦福大学和加州理工学院完成研究生学习后，他在加州理工学院获得博士学位，并在哈佛大学完成博士后培训。并且，如上所述，曾担任多家上市公司的董事和/或高级管理人员。
- Amit Kumar has served as Anixa Biosciences, Inc. President and Chief Executive Officer since July 2017 as a director of the Company since November 2012 and as Chairman of the Board since August 2016. From June 2015 until August 2016 he served as Vice Chairman of the Board. Dr. Kumar served as a strategic advisor to the Company from September 2012 until July 2017. He has been Executive Chairman of the board of directors of Anixa Diagnostics Corporation, a wholly-owned subsidiary of the Company since June 2015. Upon his appointment as Executive Chairman, Dr. Kumar resigned from his position as the Chief Executive Officer of Geo Fossil Fuels LLC, an energy company, which he had held since December 2010. From September 2001 to June 2010 he was President and Chief Executive Officer of CombiMatrix Corporation, a NASDAQ listed biotechnology company, and also served as director from September 2000 to June 2012. He was Vice President of Life Sciences of Acacia Research Corporation, a publicly traded investment company, from July 2000 to August 2007 and also served as a director from January 2003 to August 2007. Dr. Kumar has served as Chairman of the board of directors of Ascent Solar Technologies, Inc., a publicly-held solar energy company, since June 2007. He served as a director of Aeolus Pharmaceuticals, Inc., a publicly traded biotechnology company, from June 2004 to June 2018. Dr. Kumar is Chairman of Actym Therapeutics, a private biotechnology company. Dr. Kumar has served on the board of the American Cancer Society since 2016. Dr. Kumar holds an A.B. in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and completed his post-doctoral training at Harvard University. And, as described above, has served as a director and/or officer of various publicly traded companies.